Lancet Diabetes & Endocrinology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname The Lancet Diabetes & Endocrinology Volume 7 Issue 8 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Lancet diabetes & endocrinology ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tunon, J, White, H D, Zeiher, A M, Schwartz, G S, Steg, P G, Schwartz, G G, Steg, P G, ODYSSEY OUTCOMES Committees and Investigators, Clemmensen, P, Gislason, G, Nielsen, P K, Davidsen, F, Andersen, D, Jeppesen, J & Videbæk, L 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA Lancet Diabetes and Endocrinology, 7(8), 618-628. ELSEVIER SCIENCE INC
The New England journal of medicine, vol. 372, no. 25, pp. 2387-2397 Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Cannon, C P, Blazing, M A, Giugliano, R P, McCagg, A, White, J A, Theroux, P, Darius, H, Lewis, B S, Ophuis, T O, Jukema, J W, De Ferrari, G M, Ruzyllo, W, De Lucca, P, Im, K, Bohula, E A, Reist, C, Wiviott, S D, Tershakovec, A M, Musliner, T A, Braunwald, E, Califf, R M, IMPROVE-IT Investigators & Clemmensen, P M 2015, ' Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes ', The New England Journal of Medicine, vol. 372, no. 25, pp. 2387-2397 . https://doi.org/10.1056/NEJMoa1410489 New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2015, 372 (25), pp.2387-97. ⟨10.1056/NEJMoa1410489⟩ New England Journal of Medicine, 372(25), 2387-2397 New England journal of medicine, 372(25), 2387-2397. Massachussetts Medical Society